

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Original Research

Long-term excess risk of breast cancer after a single breast density measurement



Matejka Rebolj^{a,b,*}, Oleg Blyuss^{b,d}, Kee Seng Chia^c,
Stephen W. Duffy^{b,**}

^a Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, UK

^b Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK

^c Saw Swee Hock School of Public Health, National University of Singapore, Singapore

^d Department of Paediatrics, Sechenov University, Moscow, Russia

Received 12 March 2019; received in revised form 2 May 2019; accepted 3 May 2019

Available online 21 June 2019

KEYWORDS

Breast cancer;
Breast density;
Excess risk;
Screening;
Mammography

Abstract *Aim:* Breast density is a risk factor for breast cancer. As density changes across a woman's life span, we studied for how long a single density measurement taken in (post-)menopausal women remains informative.

Methods: We used data from Singaporean women who underwent a single mammography screen at age 50–64 years. For each case with breast cancer diagnosed at screening or in the subsequent 10 years, whether screen detected or diagnosed following symptoms, two age-matched controls were selected. We studied the excess risk of breast cancer, calculated as an odds ratio (OR) with conditional logistic regression and adjusted for body mass index, associated with 26–50% and with 51–100% density compared with ≤25% density by time since screening.

Results: In total, 490 women had breast cancer, of which 361 were diagnosed because of symptoms after screening. Women with 51–100% breast density had an excess risk of breast cancer that did not seem to attenuate with time. In 1–3 years after screening, the OR was 2.22 (95% confidence interval [CI]: 1.07–4.61); in 4–6 years after screening, the OR was 4.09 (95% CI: 2.21–7.58), and in 7–10 years after screening, the OR was 5.35 (95% CI: 2.57–11.15). Excess risk with a stable OR of about 2 was also observed for women with 26–50% breast density. These patterns were robust when the analyses were limited to post-menopausal women, non-users of hormonal replacement therapy and after stratification by age at density measurement.

* Corresponding author: Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, UK.

** Corresponding author:

E-mail addresses: matejka.rebolj@kcl.ac.uk (M. Rebolj), s.w.duffy@qmul.ac.uk (S.W. Duffy).

<https://doi.org/10.1016/j.ejca.2019.05.009>

0959-8049/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Conclusion: A single breast density measurement identifies women with an excess risk of breast cancer during at least the subsequent 10 years.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

About 40% of women have heterogeneously or extremely dense breasts (as defined by Breast Imaging-Reporting and Data System [BI-RADS], categories 3–4; this typically involves dense tissue in $\geq 50\%$ of the breast), of which ca. 5–10% have extremely dense breasts (BI-RADS 4; typically $\geq 75\%$ dense tissue) [1,2]. In an extensive meta-analysis, adjusted for age, the relative risk (RR) of breast cancer in women with 50–74% dense breast tissue approached three (RR: 2.92, 95% CI: 2.49–3.42) compared with women whose breasts are composed of $>95\%$ fatty tissue, while the relative risk in women with $\geq 75\%$ dense tissue was estimated to be about 4–5 (RR: 4.64, 95% CI: 3.64–5.91) [3].

Dense breast tissue is mainly fibroglandular and appears white instead of translucent on a mammogram, and this whiteness can mask prevalent cancers [4]. At least 29% (95% CI: 27–31) of cancers in dense breasts are not detectable by mammography [5]. In a US study, taking into account symptomatic cancers diagnosed 2 years after a negative screening mammogram, the mammographic sensitivity was 72% overall, but only 30% in women with extremely dense and 60% in women with heterogeneously dense breasts, whereas, it was 80% in women with predominantly fatty breasts [6].

Breast density changes across a woman's life course [7,8]. Most prominently, it decreases with age and, independently, with menopausal transition, as fibroglandular tissue is replaced with fat [9,10]. While density is associated with several non-modifiable factors such as genetics and race [11,12], various modifiable factors also play a role such as women's lifestyles [7,11,13–17] and use of medication, such as hormonal replacement therapy (HRT), which increases density, or tamoxifen, which reduces it [7,17–22].

Given this dynamic in breast density, we investigated for how long a single density measurement taken at ≥ 50 years of age remains predictive of the excess risk of breast cancer.

2. Material and methods

2.1. Study population

The study population was described in detail previously [23–28]. Briefly, all women permanently residing in Singapore in 1994 aged 50–64 years ($N = 166,600$) were

randomised to either a single round of breast screening with mammography ($N = 69,473$) or standard care; exclusion criteria were a recent mammogram or breast biopsy, pregnancy, or history of cancer other than non-melanoma cancer. One thousand women invited to participate in the trial were aged 45–49 and 65–69 years. Between October 1994 and February 1997, 42% of the invited women underwent a two-view, film-screen, mammographic examination that was evaluated by two radiologists. Women were managed according to the most suspicious of the two readings and could be either discharged, recalled for further films or recalled for joint assessment. Women's sociodemographic characteristics were determined through a questionnaire administered at screening. Mammography screening was infrequent before the trial; after it had closed, mammography was only offered within a screening programme from 2002 onward, but the coverage rate was below 40% [29]. The trial was approved by the National University of Singapore Institutional Review Board.

Information on all breast cancers (including invasive and ductal carcinoma in situ cases and both screen-detected cases as well as those diagnosed following symptoms) was retrieved until 2005 from pathology records of the two participating screening hospitals or through linkage with the national cancer registry. Each screened woman with a breast cancer diagnosis ($N = 491$) was matched on age and ethnicity with two women ($N = 982$) with a mammogram who had not developed breast cancer; the same selection of cases and controls was studied previously by Wong et al. [25].

2.2. Breast density measurements

Density was estimated retrospectively using screening mammograms from both the cases and their matched controls. Although this work was undertaken after the case-control status had become known, the final disease status was not revealed during the density scoring process. Percent breast density was estimated in the contralateral breast using the quantitative Cumulus interactive threshold method [30]. This information was not used for clinical management.

2.3. Statistical analysis

The differences in the distributions of dichotomised sociodemographic risk factors (at most primary level of education, age at menarche ≤ 14 years, premenopausal

Table 1
Description of the studied women at the time of screening, by mode of cancer detection.

N	All cancers			Screen-detected cancers			Symptomatic cancers		
	Cases	Controls	P	Cases	Controls	P	Cases	Controls	P
	491	982		129	258		362	724	
Age, mean (SD)	57.4 (4.0)	57.3 (4.1)	NR	57.9 (4.1)	57.8 (4.5)	NR	57.2 (4.0)	57.2 (4.0)	NR
Age, median (IQR)	56.6 (54.3–60.5)	56.6 (54.1–60.6)	NR	57.4 (54.7–61.2)	57.2 (53.9–61.4)	NR	56.3 (54.2–60.2)	56.5 (54.2–60.3)	NR
BMI, median (IQR)	24.7 (22.4–27.2)	23.9 (21.5–26.7)	<0.01	24.8 (21.8–26.7)	23.8 (21.4–26.6)	0.48	24.6 (22.6–27.4)	24.0 (21.6–26.8)	<0.01
% Chinese	422 (86%)	844 (86%)	NR	112 (87%)	224 (87%)	NR	310 (86%)	620 (86%)	NR
No or primary education	322 (68%)	753 (77%)	<0.01	92 (71%)	204 (79%)	0.09	240 (66%)	549 (76%)	<0.01
Age at menarche ≤14 years	295 (60%)	514 (52%)	<0.01	75 (58%)	125 (48%)	0.07	220 (61%)	389 (54%)	0.02
Premenopausal	71 (14%)	109 (11%)	0.03	18 (14%)	37 (14%)	0.90	53 (15%)	72 (10%)	0.01
No live births	70 (14%)	95 (10%)	<0.01	23 (18%)	28 (11%)	0.07	47 (13%)	67 (9%)	0.06
Ever used HRT	90 (19%)	130 (13%)	<0.01	18 (14%)	35 (14%)	0.92	72 (20%)	95 (13%)	<0.01

BMI, body mass index; HRT, hormonal replacement therapy; NR, not relevant; this was a matching variable, so inference is not applicable; IQR, interquartile range; SD, standard deviation.

status, no live births and ever using HRT) between cases and their matched controls were assessed with conditional logistic regression. For the continuous measures of body mass index (BMI) and percent density, the differences (calculated as: $[\text{BMI control1} + \text{BMI control2} - 2 \times \text{BMI case}] / 2$ and equivalent for percent density) were assessed using the t test. A Shapiro-Wilk test for non-normality was not significant: $P = 0.42$ for BMI and $P = 0.77$ for percent density. The differences between cases and controls in the categorical distributions of breast density (classified as 0–10%, 11–25%, 26–50%, 51–75% and 76–100%) were evaluated using the χ^2 statistic.

The risk of breast cancer associated with breast density was calculated with conditional logistic regression. When the risk was calculated by year since screening, percent density was categorised as $\leq 25\%$, 26–50% and $\geq 51\%$ to avoid cells with small numbers. To keep the models simple, they were adjusted for BMI only, while age and ethnicity were controlled for in the matching. In an earlier analysis of the same data set [25], further adjustment for age at menarche, number of deliveries, age at first birth, use of oral contraceptives, HRT use and menopausal status did not substantially change the BMI-adjusted overall odds ratios (ORs) for the association of density with breast cancer risk.

All analyses were undertaken with R Studio, version 1.1.419.

3. Results

Of the 491 cancers, 129 (26%) were detected at screening within the trial, and 362 (74%) were diagnosed outside of the trial, most likely as a result of seeking medical advice for symptoms. Among the 491 cases, three (1%) were younger than 50 years at screening, 157 (32%) were aged 50–54, 196 (40%) were aged 55–59, 115 (23%) were aged 60–64 and 20 (4%) were aged ≥ 65 years. Cases were statistically significantly less likely to have at most primary education than controls; they were also more likely to have a higher BMI, be younger at menarche, to have ever used HRT and were slightly more likely to be nulliparous and premenopausal (Table 1). These relationships were roughly preserved after stratification by mode of detection, although the numbers were smaller for women with screen-detected cancers, and the differences did not reach statistical significance.

Cases had significantly denser breasts than controls, with 22% of cases and 41% of controls having 0–25% density and 34% of cases and 19% of controls having 51–100% density (Table 2). Cases had on average 42%

Table 2
Description of breast density patterns among the studied women, by mode of cancer detection.

N	All cancers			Screen-detected cancers			Symptomatic cancers		
	Cases	Controls	P	Cases	Controls	P	Cases	Controls	P
	491	982		129	258		362	724	
0–10%	33 (7%)	117 (12%)	<0.01	3 (2%)	33 (13%)	<0.01	30 (8%)	84 (12%)	<0.01
11–25%	76 (15%)	282 (29%)		19 (15%)	76 (29%)		57 (16%)	206 (28%)	
26–50%	215 (44%)	391 (40%)		58 (45%)	98 (38%)		157 (43%)	293 (40%)	
51–75%	151 (31%)	171 (17%)		42 (33%)	45 (17%)		109 (30%)	126 (17%)	
76–100%	16 (3%)	21 (2%)		7 (5%)	6 (2%)		9 (2%)	15 (2%)	
Mean percent (SD)	42 (20)	33 (19)	<0.01	46 (20)	33 (20)	<0.01	41 (20)	34 (19)	<0.01

SD, standard deviation.

Table 3
Risk of breast cancer (expressed as odds ratios) by breast density and mode of detection, adjusted for BMI.

	All cancers	Screen-detected cancers	Symptomatic cancers
Cases/controls	490/980	129/258	361/722
Breast density			
0–10%	1 (ref)	1 (ref)	1 (ref)
11–25%	1.14 (0.70–1.85)	4.32 (1.11–16.79)	0.86 (0.51–1.47)
26–50%	2.67 (1.69–4.18)	11.53 (3.00–44.33)	1.93 (1.18–3.15)
51–75%	4.66 (2.83–7.65)	22.24 (5.36–92.27)	3.32 (1.93–5.69)
76–100%	5.74 (2.54–12.95)	33.74 (5.70–199.80)	3.54 (1.32–9.52)
Per 1 percentage point increase	1.03 (1.02–1.04)	1.04 (1.03–1.06)	1.03 (1.02–1.04)

BMI, body mass index.

Three women (1 case, 2 controls) had an unknown BMI, and these trios were excluded from the analysis.

of the mammogram area composed of dense tissue, whereas in controls, this was 33% ($P < 0.01$). Breast density was correlated with age. Cases aged 50–54 years had a median percent density of 48, those aged 55–59 years had 40 and those aged 60–64 years had 35. Among controls, this was 38, 31 and 23, respectively (data not tabulated).

As expected, the risk of cancer detected at screening or in the subsequent 10 years increased with percentage of breast density, with about a five-fold increase in the risk in women with $\geq 51\%$ density compared with women with $\leq 10\%$ density (Table 3; OR for 51–75% density: 4.66, 95% CI: 2.83–7.65 and OR for 76–100% density: 5.74, 95% CI: 2.54–12.95). Each percentage point increase in breast density was estimated to increase the risk of cancer by 3% (95% CI: 2–4). While the risk was substantially more pronounced for screen-detected cancers, it remained statistically significantly increased for symptomatic cancers.

Only 19 (5%) of the 361 symptomatic cancers in our study were diagnosed within the first year after screening, and the effect of breast density was not statistically significant (Table 4). Four to six years after screening when 150 (42%) symptomatic breast cancers were diagnosed, women with 26–50% density had an OR of breast cancer of 2.17 (95% CI: 1.27–3.71) compared with those with $\leq 25\%$ density, and those with 51–100% had an OR of 4.09 (95% CI: 2.21–7.58). One hundred sixteen (32%) symptomatic cancers were diagnosed 7 or more years after screening, when women with 26–50% density still had an increased risk of breast

cancer with an OR of 2.46 (95% CI: 1.32–4.58), as did women with $\geq 51\%$ density, OR 5.35 (95% CI: 2.57–11.15). A test for interaction between breast density and time since screening was not significant, and consequently, an interaction term was not included in the models.

The same patterns were observed when the analysis was restricted to 270 (75%) out of 362 symptomatic cancer case-control trios in which all three women were post-menopausal; when restricted to 227 (63%) of trios in which none of the women previously took HRT; when the analysis included only 310 (86%) trios that comprised of women of Chinese origin and when stratified by age group (< 56 years versus ≥ 56 , the sample's median; data not reported).

4. Discussion

A single mammographic measurement showing high breast density around or after menopause has long-term informational value for a woman's excess risk of developing breast cancer. In our predominantly post-menopausal sample of women undergoing a single mammography screen at age 50–64 years, the overall relative risk was about four in those with dense tissue covering at least half of their mammogram area compared with those with dense tissue in less than a quarter of their mammogram. This relationship was robust when analyses were stratified by age, post-menopausal status and use of HRT. This risk remained significantly elevated for at least 10 years and did not

Table 4
Risk of symptomatic breast cancer (expressed as odds ratios) by breast density and time since screening, adjusted for BMI.

	Total	<1 year	1–3 years	4–6 years	7–10 years
Cases/controls	361/722	19/38	76/152	150/299	116/233
Breast density					
0–25%	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
26–50%	2.13 (1.53–2.97)	3.73 (0.89–15.73)	1.67 (0.87–3.22)	2.17 (1.27–3.71)	2.46 (1.32–4.58)
51–100%	3.70 (2.53–5.42)	2.87 (0.64–12.84)	2.22 (1.07–4.61)	4.09 (2.21–7.58)	5.35 (2.57–11.15)
Per 1 percentage point increase in breast density	1.03 (1.02–1.04)	1.01 (0.99–1.04)	1.02 (1.01–1.04)	1.03 (1.02–1.04)	1.03 (1.02–1.04)

BMI, body mass index.

Three women (1 case, 2 controls) had an unknown BMI, and these trios were excluded from the analysis.

show a tendency to decline towards the end of the observation period.

To detect cancers in women with dense breasts missed by mammography, some countries are now offering complementary ultrasound screening [31]. Our results suggest that women with high breast density at age ≥ 50 years could be scheduled to undergo supplementary ultrasound screening and remain being considered for the dual screening modality for the following 10 years. Nevertheless, additional studies would need to confirm whether this approach could be cost-effective and feasible given the available health-care capacities.

Our study was undertaken in a population of Asian descent with a somewhat higher average percent breast density than in many Western populations, although the proportion of women with $\geq 50\%$ density was not exceptionally high [7,10,32]. Women in the trial underwent a single mammographic screen, although we could not ascertain whether any of them obtained additional mammography elsewhere, e.g. through the national screening programme rolled out in 2002. The Singapore cancer registry is highly complete [33], and emigration from the country was not high at least during the 1990's [34], leading to limited, if any, misclassification of case-control status in our study.

The observation that the ORs were substantially higher for screen-detected cancers than for symptomatic cancers may be somewhat surprising. These ORs are driven not by very high rates of cancer detection in dense breasts but very low rates in non-dense breasts (Table 2). They are partly dependent on the baseline category. In our analysis, this was very non-dense ($\leq 10\%$), a relatively rare group in this population, which we suspect is confounded with a number of important but unobserved risk factors. If we had chosen $\leq 25\%$ density as our baseline category, the ORs would have been of the order of 1.5–2 times higher for screen-detected, rather than 10 times higher as in Table 3. The results remain surprising, although not completely unprecedented. For example, Nickson et al. [35] found a greater risk gradient with density for large screen-detected cancers than for interval cancers.

Our results are broadly consistent with those from earlier European and Northern American studies. Byrne et al. [36] collected data from women who underwent screening in the United States in the 1970's, and those with $\geq 75\%$ breast density (as compared with those with 0% density) retained about a four-fold excess risk in 5 or more years after screening (OR: 3.56, 95% CI: 1.8–7.0, in 5–9.9 years and 4.47, 95% CI: 2.1–9.6, in 10–16 years). From Canada, Boyd et al. [32] reported an OR of 5.5 (95% CI: 2.7–11.2) in more than 4 years after screening for $\geq 75\%$ versus $< 10\%$ density. In Sweden, Chiu et al. [37] showed that the cumulative incidence of breast cancer remained significantly increased over a 25-year period for women with dense breast patterns

compared with women with non-dense breast patterns. An overall hazard ratio was 1.57 (95% CI: 1.23–2.01), and the differences between the two groups did not appear to diminish over time. Nevertheless, two other US studies showed some attenuation of the excess risk with time since density measurement, for example Thomas et al. [38] reported an OR of 3.4 (95% CI: 1.9–6.3) in 3–5 years and 2.9 (95% CI: 1.4–6.3) in ≥ 6 years for $\geq 70.3\%$ versus $\leq 26.7\%$ density, while Yaghjian et al. [39] reported an OR of 3.91 (95% CI: 2.22–6.88) in 5–9 years for $\geq 50\%$ versus $< 10\%$ density, but a lower and not statistically increased OR of 1.22, 95% CI: 0.42–3.57, beyond 9 years.

The fact that a single density measure in post-menopausal women retains its informational value in the long term may be related to a gradual stabilisation of the decline in breast density after menopause. McCormack et al. [10] estimated that breast density declines by 1.4% (95% CI: 1.2–1.6) per year around age 50 years and by 0.7% (95% CI: 0.6–0.9) around age 57 years, but that the decline is almost 0% per year around age 65 years. Using cross-sectional data from 22 countries, Burton et al. [40] found that mean percent breast density declined from 27.4% at 45–49 years of age to 22.5% at 50–54 and 18.7% at 55–59 years and then stabilised around 17% from age 60 years onward. Very similar patterns were observed in multiple other studies [7,18]. This stabilisation of breast density after menopausal transition leads to a high degree of 'tracking', whereby women whose breast density ranked high on the initial mammograms still rank high on later mammograms despite absolute changes from the earlier to the later time point [10].

Another reason for density measurements retaining their association with breast cancer in the long term may be the relative inelasticity of breast cancer risk to a declining breast density. Women with initially high density do not experience a substantially decreased risk even in the event that their breast density decreases at a later age [41,42]. Consequently, sequential measurements of breast density improve the prediction of breast cancer risk only marginally and if so, predominantly in women with additional risk factors [42].

For a woman's excess risk of breast cancer to diminish to a meaningful degree, the decrease in density may need to be substantially larger than the spontaneous changes brought about by ageing and menopause, estimated at about 1% per year [7,9,10,41]. This was demonstrated in the International Breast Cancer Intervention Study where cancer-free high-risk women aged 30–70 years were randomly assigned to either tamoxifen or placebo for 5 years [22]. Among those who used tamoxifen, 48% experienced a reduction of breast density of $\geq 10\%$ points in on average 1–1.5 years after the start of the trial. This sudden large change in density decreased the risk of cancer by 63% (95% CI: 31–80) compared with all women on placebo.

5. Conclusion

A single high breast density measurement identifies (post-menopausal) women who continue to have an excess risk of breast cancer for at least 10 years.

Conflict of interest statement

The authors declare no potential conflict of interest related to this work.

Funding

M.R. was supported by Cancer Research UK (grant number: C8162/A16892).

O.B. and SWD. contributed to this study as part of the programme of the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, which receives funding for a research programme from the Department of Health Policy Research Programme (106/0001). It is a collaboration between researchers from seven institutions (Queen Mary University of London, University College London, King's College London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham University and Peninsula Medical School).

The trial was supported by Singapore National Medical Research Council.

The funders had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the article for publication.

Acknowledgements

The authors would like to thank CS Wong, GH Lim, F Gao, RW Jakes and J Offman for collecting the updated follow-up data on the women included in this trial, which formed the basis for the herein reported analysis.

References

- [1] Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, et al. Prevalence of mammographically dense breasts in the United States. *J Natl Cancer Inst* 2014;106.
- [2] Timmermans L, Bleyen L, Bacher K, Van Herck K, Lemmens K, Van Ongeval C, et al. Screen-detected versus interval cancers: effect of imaging modality and breast density in the Flemish breast cancer screening programme. *Eur Radiol* 2017;27:3810–9.
- [3] McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomark Prev* 2006;15:1159–69.
- [4] Assi V, Warwick J, Cuzick J, Duffy SW. Clinical and epidemiological issues in mammographic density. *Nat Rev Clin Oncol* 2011;9:33–40.
- [5] Rebolj M, Assi V, Brentnall A, Parmar D, Duffy SW. Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. *Br J Canc* 2018;118:1559–70.
- [6] Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. *J Natl Cancer Inst* 2000;92:1081–7.
- [7] Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. *Cancer Epidemiol Biomark Prev* 2006;15:732–9.
- [8] Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, et al. Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health across the Nation. *Int J Cancer* 2009;124:1169–77.
- [9] Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. *Cancer Epidemiol Biomark Prev* 2002;11:1048–53.
- [10] McCormack VA, Perry NM, Vinnicombe SJ, Dos Santos Silva I. Changes and tracking of mammographic density in relation to Pike's model of breast tissue aging: a UK longitudinal study. *Int J Cancer* 2010;127:452–61.
- [11] Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, et al. The relative importance of genetics and environment on mammographic density. *Cancer Epidemiol Biomark Prev* 2009;18:102–12.
- [12] McCarthy AM, Keller BM, Pantalone LM, Hsieh MK, Synnestvedt M, Conant EF, et al. Racial differences in quantitative measures of area and volumetric breast density. *J Natl Cancer Inst* 2016;108.
- [13] Yaghjian L, Colditz GA, Rosner B, Bertrand KA, Tamimi RM. Reproductive factors related to childbearing and mammographic breast density. *Breast Canc Res Treat* 2016;158:351–9.
- [14] Lope V, Garcia-Perez J, Perez-Gomez B, Pedraza-Flechas AM, Alguacil J, Gonzalez-Galarzo MC, et al. Occupational exposures and mammographic density in Spanish women. *Occup Environ Med* 2018;75:124–31.
- [15] Masala G, Assedi M, Ambrogetti D, Sera F, Salvini S, Bendinelli B, et al. Physical activity and mammographic breast density in a Mediterranean population: the EPIC Florence longitudinal study. *Int J Cancer* 2009;124:1654–61.
- [16] Lindgren J, Dorgan J, Savage-Williams J, Coffman D, Hartman T. Diet across the lifespan and the association with breast density in adulthood. *Int J Breast Cancer* 2013;2013:808317.
- [17] Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, et al. Breast cancer risk factors in relation to breast density (United States). *Cancer Causes Control* 2006;17:1281–90.
- [18] Hellmann SS, Lyng E, Schwartz W, Vejborg I, Njor SH. Mammographic density in birth cohorts of Danish women: a longitudinal study. *BMC Canc* 2013;13:409.
- [19] Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. *Cancer Epidemiol Biomark Prev* 1999;8:863–6.
- [20] Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy. *Surgery* 1997;122:669–73. discussion 73–4.
- [21] Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. *J Am Med Assoc* 2001;285:171–6.
- [22] Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. *J Natl Cancer Inst* 2011;103:744–52.
- [23] Ng EH, Ng FC, Tan PH, Low SC, Chiang G, Tan KP, et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and

- detection of breast carcinoma among Asian women: the Singapore Breast Screening Project. *Cancer* 1998;82:1521–8.
- [24] Jakes RW, Duffy SW, Ng FC, Gao F, Ng EH. Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women. *Int J Epidemiol* 2000;29:11–9.
- [25] Wong CS, Lim GH, Gao F, Jakes RW, Offman J, Chia KS, et al. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. *Br J Canc* 2011;104:871–4.
- [26] Duffy SW, Jakes RW, Ng FC, Gao F. Interaction of dense breast patterns with other breast cancer risk factors in a case-control study. *Br J Canc* 2004;91:233–6.
- [27] Gao F, Machin D, Chow KY, Sim YF, Duffy SW, Matchar DB, et al. Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study). *BMC Canc* 2012;12:529.
- [28] Gao F, Chia KS, Ng FC, Ng EH, Machin D. Interval cancers following breast cancer screening in Singaporean women. *Int J Cancer* 2002;101:475–9.
- [29] Loy EY, Molinar D, Chow KY, Fock C. National breast cancer screening programme, Singapore: evaluation of participation and performance indicators. *J Med Screen* 2015;22:194–200.
- [30] Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. *Radiographics* 1998;18:1587–98.
- [31] Weigert J, Steenbergen S. The Connecticut experiment: the role of ultrasound in the screening of women with dense breasts. *Breast J* 2012;18:517–22.
- [32] Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. *N Engl J Med* 2007;356:227–36.
- [33] Fung JW, Lim SB, Zheng H, Ho WY, Lee BG, Chow KY, et al. Data quality at the Singapore Cancer Registry: an overview of comparability, completeness, validity and timeliness. *Cancer Epidemiol* 2016;43:76–86.
- [34] Teng YM. The Singapore state's response to migration. *Sojourner* 1999;14:198–211.
- [35] Nickson C, Arzhaeva Y, Aitken Z, Elgindy T, Buckley M, Li M, et al. AutoDensity: an automated method to measure mammographic breast density that predicts breast cancer risk and screening outcomes. *Breast Cancer Res* 2013;15:R80.
- [36] Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. *J Natl Cancer Inst* 1995;87:1622–9.
- [37] Chiu SYH, Duffy S, Yen AMF, Tabar L, Smith RA, Chen HH. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of Swedish mammographic screening. *Cancer Epidemiol Biomark Prev* 2010;19:1219–28.
- [38] Thomas DB, Carter RA, Bush Jr WH, Ray RM, Stanford JL, Lehman CD, et al. Risk of subsequent breast cancer in relation to characteristics of screening mammograms from women less than 50 years of age. *Cancer Epidemiol Biomark Prev* 2002;11:565–71.
- [39] Yaghjian L, Colditz GA, Rosner B, Tamimi RM. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram. *Cancer Epidemiol Biomark Prev* 2013;22:1110–7.
- [40] Burton A, Maskarinec G, Perez-Gomez B, Vachon C, Miao H, Lajous M, et al. Mammographic density and ageing: a collaborative pooled analysis of cross-sectional data from 22 countries worldwide. *PLoS Med* 2017;14. e1002335.
- [41] Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB. Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer. *Int J Cancer* 2014;135:1740–4.
- [42] Kerlikowske K, Gard CC, Sprague BL, Tice JA, Miglioretti DL, Breast Cancer Surveillance C. One versus two breast density measures to predict 5- and 10-year breast cancer risk. *Cancer Epidemiol Biomark Prev* 2015;24:889–97.